Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven't heard anything to suggest that Springer is anything other than a legitimate organization that publishes a wide variety of books and other materials. That said, they aren't a non-profit and some research organizations have been known to sacrifice accuracy for volume.
( e.g. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171281889&txt2find=crunchbase )
Is brilacidin really....
"Available For Licensing: Yes - COVID 2019 infections" ?
That's not news.
Incredible for sure. Don't know how I missed that....glad you didn't.
(I did note the Diwan name in the Officers list but I thought it might be India's version of Smith or Jones: https://connect2india.com/Karveer-Meditech-Private-Limited/6217161/contact-details )
"But at least they finally are saying they are about to run a trial."
But the "they" isn't Nanoviricides, it's the new Theracour (Karveer). That's why I posted this:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171600199
Karveer conducts the trials and gets reimbursed by NNVC plus the old 30% kicker.
Diwan's tangled web just got tangleder.
Apparently the original (unreported) deal, has been in place for some time....
Karveer's Date of Incorporation.....22 January 2020
From the 8-K:
"June 25, 2021, when the Mutual Non-disclosure Agreement between the Parties was executed."
"Karveer and NanoViricides have executed a Master Service Agreement, dated September 15, 2021"
The same old question persists:
Even IF the science can be shown to have some validity, will the NNVC common shareholders ever benefit from it? Apparently others will benefit, as they have, even if no validity can be shown.
"This is so easy to show as false. "
Then why don't you do that.
The original comment was:
" Unfortunately, B the Wonder Drug turns into B I Wonder Why We Wasted Our Money On This Drug once it tries to cure anything at the human level."
What's false about it?
This is false.
"Brilacidin has completed successful human Phase 1 and Phase 2 clinical trials for ABSSSI and Oral Mucositis and Ulcerative Proctitis."
Polymedix conducted a Phase 1B clinical study in PMX-30063. The data from the study demonstrate that administration of multiple doses of PMX-30063 are safe and well-tolerated at dose levels which showed bactericidal activity in blood samples drawn from subjects in the study.
When was the Phase 1 B-OM trial conducted?
The only Phase 1 trial for B-UP was to test the delayed release delivery system (which has since been abandoned and replaced with "An immediate release, multi-particulate, capsule formulation (which) has been developed, although further work has since been halted due to instability of that formulation being identified".).
The only success that has occurred in any trials related to B-ABSSSI, B-OM or B-UP has been their completion. They obviously have not "cure(d)" anything at the human level.
A clinical trial can be successful without resulting in a cure or, more importantly from an investors standpoint, a marketable drug. IPIX has done that.
"Directors of Karveer Meditech Private Limited are Vivek Prakash Kadam and Nehali Sharadchandra Diwan."
No relation, right? Right?
A Big Lie right in the headline:
"NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All"
" WHEREAS, Karveer, as the Drug Sponsor in India, has received regulatory authorization from the New Drug Division, CDSCO, Govt. of India, to conduct the Clinical Trials of the first of the Two Clinical Test Drug Candidates, NV-CoV-2, for its first in Human Phase Ia/Ib human clinical trial in India"
Anybody paying attention?
https://covid19.who.int/table
https://www.google.com/search?q=population+of+india&oq=population+of+india&aqs=chrome..69i57j0i67i650j0i433i512l2j0i20i263i512j0i131i433i512j0i512l4.8578j1j15&sourceid=chrome&ie=UTF-8
"How is that Phase 3 study going?"
Good question. It's NOT going, unless Leo is keeping it between himself and Galera.
Here's what he told investors in the latest 10q:
There's a table that says....
"Phase 3 planned, contingent upon sufficient funding"
and some text that says....
"Further advancement in the indication of oral mucositis requires additional drug formulation/analytical work, followed by clinical trial supply manufacturing prior to progressing to Phase 3 clinical trials. Given the low price per share of our common stock and the many multiple million dollar costs associated with a Phase 3 program, at this time clinical trial supply manufacturing and Phase 3 clinical trial conduct are delayed, with such activities pending securing sufficient working capital and/or partnership."
(highlight mine)
It's ironic that Galera can say this about B-OM but IPIX can't (without putting itself in some legal jeopardy):
"There are several drugs in clinical development for oral mucositis – two in Phase 3 (brilacidin by Innovation Pharmaceuticals, Inc., and a mucobuccal tablet by Monopar Therapeutics LLC) and one submitted for a NDA (GC4419 by Galera Therapeutics, Inc.)."
Think anyone is gonna have the chutzpah to say that saying that "at this time clinical trial supply manufacturing and Phase 3 clinical trial conduct are delayed" doesn't mean that B-OM isn't in Phase 3? Wouldn't surprise me. Wait for it!
Since the date that CTIX bought the Polymedix assets its share price went from $2.07 to $.02.
During the same period Regeneron's share price went from $300 to $820. And Ihub says they had $12B in revenue in the last year.
Like two peas in a pod.
"Is the company science good or not good?"
So far it seems to be wanting. You need look no further than this:
IPIX
Innovation Pharmaceuticals Inc (QB)
0.02
0.00 (0.00%)
Volume: 328,855
Tell me the Regeneron story again.
The comparison makes me laugh.
https://www.regeneron.com/about/history
"You are desperate to link Brilacidin to a anti-fungus drug product tested and rejected by Basilea."
Bullshit...for the third time. I'm merely posting the truth.
I have nothing to lose....why would I be desperate?
You, on the other hand......
"You also say "Dr. Scott was involved in the beginnings of brilacidin"."
Dr. Scott himself said so.
"As Vice President of Research at PolyMedix Inc., I led the research team responsible for the identification of the clinical lead compound, brilacidin, that successfully completed a Phase 2 clinical study for treatment of acute bacterial skin and skin structure infections (ABSSSI)."
So does your leader CEO LEO
https://www.biospace.com/article/releases/innovation-pharmaceuticals-exploring-lead-defensin-mimetic-drug-candidate-brilacidin-as-potential-novel-coronavirus-treatment/
"Pre-clinical research also supports Brilacidin’s antiviral properties based on work by conducted by Dr. William DeGrado (UCSF) and Dr. Richard Scott (Fox Chase)."
and DeGrado
https://pubmed.ncbi.nlm.nih.gov/24936592/
"You suggest Basilea tested Brilacidin and rejected it."
Bullshit. I didn't suggest it then and I'm not saying it now.
A careful reading of the post wouldn't have lead you to that conclusion. The reference to Dr Scott included the only mention of brilacidin and it's 11 years old.
That said, Dr. Scott was involved in the beginnings of brilacidin and also worked on the anti-fungals. He links to both activities, like it or not. If either of those things had proven fruitful you would undoubtedly be thrilled with that connection. Alas, they haven't. Unless you consider a $418k return on "USD $2.1 million cash plus 1.4 million Ctix shares" (worth 100 times more then than they are now) a fruitful investment.
Hope you've enjoyed the ride so far.
You're welcome. Unfortunately you and I have a bigger web presence than AIMH's new running buddy ( Discharger Capital LLC) so there's not much to offer. It's a Wyoming llc using it's agent's street address and that's all I could find. Same with Russell Lee White....maybe someone else can do better.
It's interesting that the PR was signed by Stauber. Is Sexton gone?
SOMEONE updated OTCMarkets to show that it now has the luxury of having TWO Presidents:
"Adam Sexton
President, CEO, Treasurer
Russell Lee White
President, Chief Accounting Officer"
“A discussion of the Company’s business operations and services and updated financial information will be included in the March 31, 2023, quarterly filing.”
That report isn't due until mid-May. There should be a discussion of the Company’s business operations and services and updated financial information in the Annual Report, due tomorrow.
The author should have.....it was misused (if I understand what was meant by it).
False on both counts.
This stuff:
https://www.fiercebiotech.com/biotech/first-hiccup-basileas-anti-infective-strategy-biotech-hands-back-antifungal-9-months-after
As I understand it Basilea never got brilacidin so they obviously couldn't give it back.
Richard W Scott, VP Research for Polymedix, says he "led the research team responsible for the identification of the clinical lead compound, brilacidin".
He eventually moved on to become VP Research for Fox Chase Chemical Diversity Center. In 2018 he engineered a $4M+ grant from the Dept of Defense entitled "New antifungal agents as topical and systemic therapies for wound and invasive infections".
Efforts related to that grant resulted in the license that Fox entered into with Basilea and dribbled $18K into the IPIX change purse.
Basilea thought so little of the stuff that they gave it back.
And now we have IPIX, Master of the Antifungal. It's a lock.
The rumored Company is not likely to be Basilea.
Since the reporter says "My contact says they will revert to me after the meeting" and the "European pharmaceutical company will discuss Brilacidin in their internal licensing meeting in 3 weeks", it should be easy to wait to find out who it is given the lack of any other significant IPIX activity (5 hours witohut a post speaks to that). Hopefully at that point they will be more forthcoming. Maybe IPIX itself or even the subject company will tell us who they are.....
"Less than 86 million shares left to dilute."
I suspect that the 26M added to the outstanding common number came from a conversion of the following:
"Series B 5% convertible preferred stock liability at $1,080 stated value; 620 shares issued and outstanding at December 31, 2022"
That uses up the outstanding preferred, so any new common that gets issued will have to be as a result of something else. There's not much convertible stuff left on the balance sheet.
"The FDA has the ability to sponsor public/private studies for serious infectious diseases. "
Your link doesn't say that and I don't believe that it's true.
"A European pharmaceutical company will discuss Brilacidin in their internal licensing meeting in 3 weeks. I know this direct from the company and not from Ipix."
What company is that?
If you choose not to answer please say why.
https://www.bing.com/search?form=MOZLBR&pc=MOZI&q=absssi+oral
https://www.sivextro.com/professional-resources/management-of-absssi/#:~:text=Management%20of%20ABSSSI%20Many%20patients%20with%20ABSSSI%20may,office%2C%20urgent%20care%20centers%2C%20or%20wound%20care%20centers
https://www.nuzyra.com/hcp/efficacy/absssi
https://pubmed.ncbi.nlm.nih.gov/31474458/
Note the first author listed in the above paper.
https://clinicaltrials.gov/ct2/show/NCT02052388?term=brilacidin&draw=2&rank=3
Scroll down to Principal Investigator.
An interesting coincidence.
"Lidocaine also causes temporary numbness."
Lidocaine is an anesthetic. That's exactly what it's supposed to do.
"The results sure sound like people being cured of their ABSSSI."
Not to me it doesn't.
Cure, according to Medspeak, means.....
noun: Restoration to a usual state of health.
verb: To heal, restore to health.
That's not what this says:
"In this population, Clinical Success rates at 48-72 hours were again very high (above 90% across all treatment groups) and again very similar (with overlapping 95% confidence intervals)."
Once again you have fallen for the CEO's 90%+ gibberish.
What he referred to as "Clinical Success rates at 48-72 hours" was the Primary Outcome measurement of the trial:
"The primary efficacy outcome, early clinical response 48-72 hours after the first dose of study drug, will be determined in the ITT population. A subject will be considered a Clinical Success if 1) the lesion area has decreased by ≥20% compared to baseline and 2) no additional systemic antibacterials that are potentially effective against gram positive organisms have been administered."
https://clinicaltrials.gov/ct2/show/NCT02052388?term=brilacidin&draw=2&rank=3
≥20% is not 100%. A cure would be defined as the total resolution of a lesion, not ≥20% of it.
The people who need to put enough investment dollars into this thing to move the share price in a significant way aren't likely to be slow witted enough to fall for your misleading interpretation of this CEO's 90%+ tricks. They probably know what "cured" means.
Are you kidding?
All patience(sic) did not go home cured. Even Leo has never had the chutzpah to try to peddle that bullshit.
The bad spelling is forgivable but the deception isn't.
Look back at the press releases discussing results. Then look up the meaning of "cured".
Enter the term in the Search box of the IPIX website and see if you can think of a reason why it would say "no results" if "all patience in the ABSSSI trial went home cured". Sounds like maybe you can get some help with that.
What prompted this nonsense?
"In his now cancelled/removed press releases, he was holding K out as a big money maker, using his now infamous routine of comparing his drug to other million/billion dollar drugs and claiming K had the potential to surpass any on the market or in trial. Ehrlich's press releases hyped K and he boasted about being in discussions with other parties. And yet, here we sit today with K cancelled just like the prior press releases."
Like this one?
https://www.globenewswire.com/en/news-release/2020/09/08/2090209/0/en/Innovation-Pharmaceuticals-Announces-Publication-of-Independent-Research-on-Kevetrin-the-Company-s-p53-Drug-Candidate-in-Oncology-Reports.html
Easy to Google but not on the website.
http://www.ipharminc.com/press-release
Pride comes before the fall.
"These results suggest that brilacidin possesses a unique potential as a preventative agent at the mucosa (e.g. in a nasal spray)."
So a person who thought that he or she might come into contact with some Covid19 infected air would get a prescription for B-Covid nasal spray?
Did Leo tell you that in your phone chat? Because he didn't mention that prospect in the 10Q:
"Pursing(sic) a biomarker-driven approach, increasing Brilacidin dosing, targeting different patient populations, testing Brilacidin in combination with other drugs (e.g., remdesivir, given synergistic in vitro data) -- all are areas under consideration for potential future Brilacidin COVID-19 clinical trials pending obtaining government, partnership-based or other financial support."
https://www.sec.gov/Archives/edgar/data/1355250/000147793223001071/ipix_10q.htm
"IMO an urgent FDA study is needed with the death rate for the standard treatment being so high."
The FDA doesn't conduct studies, does it?
https://www.google.com/search?q=does+the+fda+conduct+studies%3F&client=firefox-b-1-d&sxsrf=AJOqlzURxMcvCeVMQJ3Fj2V45vWslCDWMQ%3A1679604009137&ei=KbkcZLnqB6Ce5NoPzde68AQ&ved=0ahUKEwj5os_C9PL9AhUgD1kFHc2rDk4Q4dUDCA8&uact=5&oq=does+the+fda+conduct+studies%3F&gs_lcp=Cgxnd3Mtd2l6LXNlcnAQAzIECCMQJzIGCAAQFhAeMgYIABAWEB4yCAgAEIoFEIYDMggIABCKBRCGAzoHCCMQsAMQJzoKCAAQRxDWBBCwA0oECEEYAFDnGVjMJGDIRWgBcAF4AIABjwGIAZICkgEDMi4xmAEAoAEByAEJwAEB&sclient=gws-wiz-serp
"Brilacidin has been tested already and showed potent activity against multi-drug resistant Candida Aureus"
Did you mean candida auris?
In case that's what you meant your statement doesn't appear to be correct. I don't think "B has been tested already and showed potent activity against multi-drug resistant candida auris" unless you count tests in combination with another drug.
I do have an idea of what the market size is in terms of persons infected (I'm pretty sure those numbers have been posted here already) but as I said I have NO idea what the dollar value of the candida auris market is.
It's interesting that Leo hasn't mentioned it....that SHOULD tell you something. He's rarely bashful about publishing the market sizes of his target indications and OTHER companies revenues generated for those targets, whether he can treat them or not.
For example:
"Caspofungin sales were estimated to be $414 million in 2021, with the global antifungal drugs market estimated at $14.8 billion in 2021 and expected to reach $20.5 billion by 2030."
Tantalizing stuff, isn't it?
But does he have a SPECIFIC plan to capture some of it?
Go ahead. Ask him what the dollar value of the candida auris market is.
And while you're at it ask him when he hopes to have a Phase 1 or 2 trial for B-Fungus (of any kind, alone or in combination with any existing anti-fungal). He'll need to do that before he makes the "when sufficient funds are available" announcement for a Phase 3, won't he?
Those were two distinctly different observations about two different markets.
If you read it carefully I won't have to explain it.
Couldn't follow the thread? It began with Candida auris and I was responding to it:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171495781
This is typical of the IPIX promotional effort since the Company began:
"*Caspofungin sales were estimated to be $414 million in 2021, with the global antifungal drugs market estimated at $14.8 billion in 2021 and expected to reach $20.5 billion by 2030.*"
Nice BIG irrelevant numbers.
Tell us about the Cubicin market again, Leo.
"With a 60+ % mortality rate, this if ever to become a pandemic would be worse than CV-19 because of the higher mortality rate in my opinion."
A few important differences:
Candida auris is very rare in otherwise healthy individuals. The CDC even says "Family members (of people with the infection) who are healthy probably have a low chance of C. auris infection."
It is predominantly a disease that occurs in healthcare facilities. Per the CDC "C. auris is mainly a problem among people who are already sick with multiple medical problems and have spent a lot of time in healthcare settings."
The 60% mortality rate needs context. Again from the CDC: "Many people who have died with C. auris had other serious illnesses that increased their risk of death."
I'm not happy about referring to a bunch of suffering individuals as a "market" but in fact this fungus is one of the smaller, if not the smallest, markets. And the powerpoint on the Company website describes "brilacidin (BRI) as a synergizer with caspofungin (CAS)", so it's a shared market.
"This clearly fits the profile for what compassionate use is designed for."
Does it?
"Expanded access may be appropriate when all the following apply:
Patient has a serious or immediately life-threatening disease or condition.
There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
Patient enrollment in a clinical trial is not possible.
Potential patient benefit justifies the potential risks of treatment.
Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication."
https://www.fda.gov/news-events/public-health-focus/expanded-access
"There is now no reason that Leo can't make a deal for Brilacidin as an anti-fungal."
That's just bloviation.
"You have NIH affiliates that have tested it against this Candida auris with great results."
Tested in things with arms and legs? Those were pre-clinical tests, right?
Not so long ago you could have made the same statement about B-Covid. Someone here is still posting about "B426".
I ask because B-ABSSSI and B-OM have both been tested in humans in Phase 2 tests, purportedly successfully and Leo hasn't made a deal. Why haven't you made this same comment about them?
"If he doesn't make a deal then he needs to step down."